


RN 404828-73-5 CAPLUS


CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-83-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

09/624,800

Thomas McKenzie

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-85-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-morpholinyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-86-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperazinyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-87-1 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperidiny)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-88-2 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-89-3 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperidinyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-90-6 CAPLUS


CN 4-Quinazolinamine, 2-(hexahydro-1H-azepin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-91-7 CAPLUS


CN 4-Piperidineethanol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-92-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidiny)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-94-0 CAPLUS


CN 4-Quinazolinamine, 2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-95-1 CAPLUS


CN 4-Quinazolinamine, 2-[4-(cyclopentylamino)-1-piperidinyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-96-2 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-97-3 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-4-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-98-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-99-5 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-00-1 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinolinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-01-2 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-02-3 CAPLUS


CN 4-Piperidinemethanol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-05-6 CAPLUS

CN Piperidine, 1-[[5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404829-06-7 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)


RN 404829-07-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-
(9CI) (CA INDEX NAME)




RN 404829-08-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(4-methyl-1-piperidiny)]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404829-54-5 CAPLUS


CN Thieno[3,2-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-55-6 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-56-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-57-8 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-60-3 CAPLUS


CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404845-75-6 CAPLUS

CN 1H-Purin-6-amine, 2-(4-methyl-1-piperidinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT **404828-81-5**, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



L11 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

2002:220578 Document No. 136:263164 Preparation of triazolamines as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. Bebbington, David; Knegetel, Ronald; Binch, Haley; Golec, Julian M. C.; Li, Pan; Charrier, Jean-Damien (Vertex Pharmaceuticals Incorporated, USA). PCT Int. Appl. WO 2002022602 A2 20020321, 377 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ,

CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US42162 20010914. PRIORITY: US 2000-PV232795 20000915; US 2000-PV257887 20001221; US 2001-PV286949 20010427.

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|--|----------|
| PI | WO 2002022602 | A2 | 20020321 | WO 2001-US42162 | 20010914 |
| | WO 2002022602 | A3 | 20020627 | | |
| | W: | | | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | |
| | RW: | | | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | |
| | AU 2001096875 | A5 | 20020326 | AU 2001-96875 | 20010914 |
| | US 2003055044 | A1 | 20030320 | US 2001-953505 | 20010914 |
| | US 6638926 | B2 | 20031028 | | |
| | US 2003064981 | A1 | 20030403 | US 2001-952836 | 20010914 |
| | US 6613776 | B2 | 20030902 | | |
| | US 2003064982 | A1 | 20030403 | US 2001-952875 | 20010914 |
| | US 2003073687 | A1 | 20030417 | US 2001-952671 | 20010914 |
| | US 6660731 | B2 | 20031209 | | |
| | US 2003078166 | A1 | 20030424 | US 2001-955601 | 20010914 |
| | US 6696452 | B2 | 20040224 | | |
| | US 2003083327 | A1 | 20030501 | US 2001-952833 | 20010914 |
| | US 6610677 | B2 | 20030826 | | |
| | EP 1318814 | A2 | 20030618 | EP 2001-977783 | 20010914 |
| | R: | | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | |
| | JP 2004509114 | T2 | 20040325 | JP 2002-526855 | 20010914 |
| | US 2004097501 | A1 | 20040520 | US 2001-953471 | 20010914 |
| | EP 1345922 | A1 | 20030924 | EP 2001-271061 | 20011219 |
| | R: | | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | |
| | EP 1355905 | A1 | 20031029 | EP 2001-273861 | 20011219 |
| | R: | | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | |
| | NZ 526472 | A | 20040430 | NZ 2001-526472 | 20011219 |
| | JP 2004518743 | T2 | 20040624 | JP 2002-565976 | 20011219 |
| | JP 2004519479 | T2 | 20040702 | JP 2002-567928 | 20011219 |
| | NO 2003002704 | A | 20030821 | NO 2003-2704 | 20030613 |
| | US 2004116454 | A1 | 20040617 | US 2003-692355 | 20031023 |
| | US 2004157893 | A1 | 20040812 | US 2003-722374 | 20031125 |
| | US 2004132781 | A1 | 20040708 | US 2003-736426 | 20031215 |
| | US 2004167141 | A1 | 20040826 | US 2004-775699 | 20040210 |
| IT | 404826-20-6P , [2-(3,4-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-21-7P , [2-(4-Bromophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-22-8P , (2-Biphenyl-4-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-23-9P , [2-(4-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H- | | | | |


pyrazol-3-yl)amine **404828-54-2P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-58-6P**, (5-Benzyloxypropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-61-1P**, [5-(3-tert-Butoxycarbonylaminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404829-04-5P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl) [2-(piperidine-1-yl)quinazolin-4-yl]amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protein kinase inhibitor; preparation of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-21-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

09/624,800

Thomas McKenzie

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl
ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




Ph-CH₂-O-(CH₂)₃

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 404829-04-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT **404826-60-4P**, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine **404826-61-5P**, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-62-6P**, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-63-7P**, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-64-8P**, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-65-9P**, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-66-0P**, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-67-1P**, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-68-2P**, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-69-3P**, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine **404826-70-6P**, (2-Biphenyl-2-yl)quinazolin-4-yl(5-methyl-2H-pyrazol-3-yl)amine **404826-71-7P**, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine **404826-72-8P**, [2-(2-

Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine
404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-74-0P**,
[4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-75-1P**, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-76-2P**,
(5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-77-3P**, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-78-4P**,
(4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-79-5P**, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-80-8P**,
(2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-81-9P**, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-82-0P**,
(5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-83-1P**, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-35-6P**,
[2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404827-56-1P**, (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404828-08-6P**, (5-Methyl-2H-pyrazol-3-yl)(2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine **404828-09-7P**,
(5-Methyl-2H-pyrazol-3-yl)(2-phenyl-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl)amine **404828-10-0P**,
(5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)-amine **404828-11-1P**, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-12-2P**, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-13-3P**,
(2-Cyclohexylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**,
[2-(3-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**, [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-22-4P**,
[2-(4-tert-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**,
[2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**,
[2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**, (5-Methyl-2H-pyrazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine

404828-37-1P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-ylquinazolin-4-yl)amine 404828-38-2P, [2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-40-6P, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-43-9P 404828-44-0P, (2-Phenylquinazolin-4-yl)(2H-pyrazol-3-yl)amine 404828-45-1P, (2H-Pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine 404828-46-2P, (5-Ethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-47-3P, (2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine 404828-48-4P, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine 404828-51-9P, (5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-52-0P, (5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-55-3P, (5-Hydroxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-56-4P, (5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl)(5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-74-6P, (2-Phenylquinazolin-4-yl)(5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl)(5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-85-9P, (5-Methyl-2H-pyrazol-3-yl)(2-morpholin-4-


ylquinazolin-4-yl)amine **404828-86-0P**, (5-Methyl-2H-pyrazol-3-yl)(2-piperazin-1-ylquinazolin-4-yl)amine **404828-87-1P**, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-88-2P**, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-89-3P**, (5-Methyl-2H-pyrazol-3-yl)(2-piperidin-1-ylquinazolin-4-yl)amine **404828-90-6P**, [2-(Azepan-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-91-7P**, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-92-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404828-94-0P**, [2-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-95-1P**, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-96-2P**, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-97-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine **404828-99-5P**, [2-(Azepan-1-yl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine **404829-02-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-05-6P**, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine **404829-06-7P**, (5-Hydroxymethyl-2H-pyrazol-3-yl)[2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-07-8P**, (5-Carbamoyl-2H-pyrazol-3-yl)[2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-08-9P**, (5-Carbamoyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404829-54-5P**, (5-Methyl-2H-pyrazol-3-yl)-(2-pyridin-4-ylthieno[3,2-d]pyrimidin-4-yl)amine **404829-55-6P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-56-7P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine **404829-57-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-60-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)pyrrolo[3,2-d]pyrimidin-4-yl]amine **404845-75-6P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-35-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-56-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-08-6 CAPLUS


CN 4-Quinazolinamine, 5,6,7,8-tetrahydro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-09-7 CAPLUS


CN 5H-Cycloheptapyrimidin-4-amine, 6,7,8,9-tetrahydro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-13-3 CAPLUS


CN 4-Quinazolinamine, 2-cyclohexyl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-15-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-16-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-17-7 CAPLUS

CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-21-3 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-36-0 CAPLUS

CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-37-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-38-2 CAPLUS

CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-48-4 CAPLUS

CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-49-5 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-


(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-53-1 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




09/624,800

Thomas McKenzie


RN 404828-55-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-57-5 CAPLUS

CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-59-7 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-60-0 CAPLUS

CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-62-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)


RN 404828-68-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)




RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-83-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

09/624,800

Thomas McKenzie

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-85-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-86-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-87-1 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperidinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-88-2 CAPLUS


CN 4-Quinazolinamine, 2-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-89-3 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-piperidinyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-90-6 CAPLUS


CN 4-Quinazolinamine, 2-(hexahydro-1H-azepin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-91-7 CAPLUS


CN 4-Piperidineethanol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-92-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-94-0 CAPLUS


CN 4-Quinazolinamine, 2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-95-1 CAPLUS


CN 4-Quinazolinamine, 2-[4-(cyclopentylamino)-1-piperidinyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-96-2 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-97-3 CAPLUS


CN 4-Piperidinol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-4-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-98-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-99-5 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-00-1 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinolinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-01-2 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-02-3 CAPLUS


CN 4-Piperidinemethanol, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-05-6 CAPLUS

CN Piperidine, 1-[[5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404829-06-7 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]- (9CI)
(CA INDEX NAME)


RN 404829-07-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-
(9CI) (CA INDEX NAME)




RN 404829-08-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[[2-(4-methyl-1-piperidinyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404829-54-5 CAPLUS


CN Thieno[3,2-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-55-6 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-56-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-57-8 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-60-3 CAPLUS


CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404845-75-6 CAPLUS

CN 1H-Purin-6-amine, 2-(4-methyl-1-piperidinyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT **404828-81-5**, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



L11 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

2002:220577 Document No. 136:247579 Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. Knegt, Ronald; Bebbington, David; Binch, Hayley; Golec, Julian; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert; Li, Pan; Wannamaker, Marion; Forster, Cornelia; Pierce, Albert (Vertex Pharmaceuticals Incorporated, USA). PCT Int. Appl. WO 2002022601

A1 20020321, 376 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US28740 20010914. PRIORITY: US 2000-PV232795 20000915; US 2000-PV257887 20001221; US 2001-PV286949 20010427.

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------|------|----------|--|----------|
| PI WO 2002022601 | A1 | 20020321 | WO 2001-US28740 | 20010914 |
| W: | | | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | |
| RW: | | | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | |
| AU 2001090914 | A5 | 20020326 | AU 2001-90914 | 20010914 |
| US 2003055044 | A1 | 20030320 | US 2001-953505 | 20010914 |
| US 6638926 | B2 | 20031028 | | |
| US 2003064981 | A1 | 20030403 | US 2001-952836 | 20010914 |
| US 6613776 | B2 | 20030902 | | |
| US 2003064982 | A1 | 20030403 | US 2001-952875 | 20010914 |
| US 2003073687 | A1 | 20030417 | US 2001-952671 | 20010914 |
| US 6660731 | B2 | 20031209 | | |
| US 2003078166 | A1 | 20030424 | US 2001-955601 | 20010914 |
| US 6696452 | B2 | 20040224 | | |
| US 2003083327 | A1 | 20030501 | US 2001-952833 | 20010914 |
| US 6610677 | B2 | 20030826 | | |
| EP 1317444 | A1 | 20030611 | EP 2001-970971 | 20010914 |
| R: | | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | |
| JP 2004509113 | T2 | 20040325 | JP 2002-526854 | 20010914 |
| US 2004097501 | A1 | 20040520 | US 2001-953471 | 20010914 |
| EP 1345922 | A1 | 20030924 | EP 2001-271061 | 20011219 |
| R: | | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | |
| EP 1355905 | A1 | 20031029 | EP 2001-273861 | 20011219 |
| R: | | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | |
| NZ 526472 | A | 20040430 | NZ 2001-526472 | 20011219 |
| JP 2004518743 | T2 | 20040624 | JP 2002-565976 | 20011219 |
| JP 2004519479 | T2 | 20040702 | JP 2002-567928 | 20011219 |
| NO 2003002704 | A | 20030821 | NO 2003-2704 | 20030613 |
| US 2004116454 | A1 | 20040617 | US 2003-692355 | 20031023 |
| US 2004157893 | A1 | 20040812 | US 2003-722374 | 20031125 |
| US 2004132781 | A1 | 20040708 | US 2003-736426 | 20031215 |
| US 2004167141 | A1 | 20040826 | US 2004-775699 | 20040210 |
| IT 404826-20-6P, | | | [2-(3,4-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine | |
| 404826-21-7P, | | | [2-(4-Bromophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine | |
| 404826-22-8P, | | | (2-Biphenyl-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine | |


404826-23-9P, [2-(4-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-54-2P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-58-6P**, (5-Benzyloxypropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-61-1P**, [5-(3-tert-Butoxycarbonylaminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404829-04-5P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl)[2-(piperidine-1-yl)quinazolin-4-yl]amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl
ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




Ph-CH₂-O-(CH₂)₃

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 404829-04-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[[2-(1-piperidiny1)-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT **404826-60-4P**, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine **404826-61-5P**, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-62-6P**, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-63-7P**, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-64-8P**, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-65-9P**, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-66-0P**, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-67-1P**, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-68-2P**, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-69-3P**, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine **404826-70-6P**, (2-Biphenyl-2-yl)quinazolin-4-yl(5-methyl-2H-pyrazol-3-yl)amine **404826-71-7P**, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine **404826-72-8P**, [2-(2-

Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine
404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-74-0P**,
[4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-75-1P**, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-76-2P**,
(5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-77-3P**, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-78-4P**,
(4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-79-5P**, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-80-8P**,
(2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-81-9P**, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-82-0P**,
(5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404826-83-1P**, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-35-6P**,
[2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404827-56-1P**, (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404828-08-6P**, (5-Methyl-2H-pyrazol-3-yl)[2-(2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine **404828-09-7P**,
(5-Methyl-2H-pyrazol-3-yl)(2-phenyl-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl)amine **404828-10-0P**,
(5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)-amine **404828-11-1P**, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-12-2P**, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-13-3P**,
(2-Cyclohexylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**,
[2-(3-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**, [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-22-4P**,
[2-(4-tert-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**,
[2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**,
[2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**, (5-Methyl-2H-pyrazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine

404828-37-1P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-ylquinazolin-4-yl)amine 404828-38-2P, [2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-40-6P, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-43-9P 404828-44-0P, (2-Phenylquinazolin-4-yl)(2H-pyrazol-3-yl)amine 404828-45-1P, (2H-Pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine 404828-46-2P, (5-Ethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-47-3P, (2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine 404828-48-4P, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine 404828-51-9P, (5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-52-0P, (5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-55-3P, (5-Hydroxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-56-4P, (5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl)(5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-74-6P, (2-Phenylquinazolin-4-yl)(5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl)(5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-85-9P, (5-Methyl-2H-pyrazol-3-yl)(2-morpholin-4-


ylquinazolin-4-yl)amine **404828-86-0P**, (5-Methyl-2H-pyrazol-3-yl)(2-piperazin-1-yl)quinazolin-4-yl)amine **404828-87-1P**, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-88-2P**, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-89-3P**, (5-Methyl-2H-pyrazol-3-yl)(2-piperidin-1-yl)quinazolin-4-yl)amine **404828-90-6P**, [2-(Azepan-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-91-7P**, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-92-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404828-94-0P**, [2-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-95-1P**, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-96-2P**, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-97-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine **404828-99-5P**, [2-(Azepan-1-yl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine **404829-02-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-05-6P**, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine **404829-06-7P**, (5-Hydroxymethyl-2H-pyrazol-3-yl)[2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-07-8P**, (5-Carbamoyl-2H-pyrazol-3-yl)[2-(piperidin-1-yl)quinazolin-4-yl]amine **404829-08-9P**, (5-Carbamoyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine **404829-54-5P**, (5-Methyl-2H-pyrazol-3-yl)-(2-pyridin-4-ylthieno[3,2-d]pyrimidin-4-yl)amine **404829-55-6P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-56-7P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine **404829-57-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-60-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)pyrrolo[3,2-d]pyrimidin-4-yl]amine **404845-75-6P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-75-1 CAPLUS

CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-76-2 CAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

